Jeff Yass’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-726,700
| Closed | -$34.1M | – | 13831 |
|
|
2025
Q2 | $34.1M | Sell |
726,700
-237,400
| -25% | -$10.6M | ﹤0.01% | 1482 |
|
|
2025
Q1 | $42.5M | Buy |
964,100
+856,800
| +799% | +$39.4M | 0.01% | 1123 |
|
|
2024
Q4 | $3.88M | Sell |
107,300
-1,900
| -2% | -$66.4K | ﹤0.01% | 4004 |
|
|
2024
Q3 | $3.5M | Buy |
109,200
+1,300
| +1% | +$48.6K | ﹤0.01% | 4264 |
|
|
2024
Q2 | $4.06M | Buy |
107,900
+91,300
| +550% | +$3.84M | ﹤0.01% | 3790 |
|
|
2024
Q1 | $817K | Sell |
16,600
-29,900
| -64% | -$1.38M | ﹤0.01% | 7365 |
|
|
2023
Q4 | $1.7M | Buy |
46,500
+36,900
| +384% | +$963K | ﹤0.01% | 5709 |
|
|
2023
Q3 | $222K | Sell |
9,600
-22,500
| -70% | -$615K | ﹤0.01% | 10010 |
|
|
2023
Q2 | $842K | Buy |
+32,100
| New | +$844K | ﹤0.01% | 7091 |
|
|
2023
Q1 | – | Sell |
-18,900
| Closed | -$492K | – | 13475 |
|
|
2022
Q4 | $492K | Buy |
18,900
+4,500
| +31% | +$111K | ﹤0.01% | 7911 |
|
|
2022
Q3 | $411K | Buy |
+14,400
| New | +$413K | ﹤0.01% | 8996 |
|
|
2022
Q2 | – | Sell |
-60,400
| Closed | -$3.41M | – | 13910 |
|
|
2022
Q1 | $3.41M | Buy |
60,400
+56,300
| +1,373% | +$3.22M | ﹤0.01% | 4381 |
|
|
2021
Q4 | $254K | Buy |
4,100
+400
| +11% | +$26.5K | ﹤0.01% | 10895 |
|
|
2021
Q3 | $235K | Buy |
3,700
+1,000
| +37% | +$77.1K | ﹤0.01% | 11141 |
|
|
2021
Q2 | $223K | Buy |
+2,700
| New | +$205K | ﹤0.01% | 11370 |
|
Other funds holding SWTX
Jeff Yass's SWTX Position: Q3 2025 in Review
Jeff Yass sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 484,874 shares — an estimated $22.8M sold.
Jeff Yass first reported a position in SWTX in Q3 2019 and held it in 20 quarters. The position peaked at $27.5M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- Jeff Yass reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- Jeff Yass sold 484,874 SpringWorks Therapeutics shares in Q3 2025, an estimated $22.8M.
- Jeff Yass first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 20 quarters.
- Jeff Yass's SpringWorks Therapeutics position peaked at $27.5M in Q1 2025.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.